CYTO logo

Altamira Therapeutics (CYTO) EBITDA

Annual EBITDA

-$1.87 M
+$17.15 M+90.15%

December 1, 2023

Summary

Performance

1-Year Change

+90.15%

3-Year Change

+79.7%

5-Year Change

+81.69%

15-Year Change

+91.95%

CYTO EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

76.75%
CYTO annual EBITDA is higher than 76.75% of companies in Healthcare sector

High & Low

All-time High

-$1.87 M
CYTO annual EBITDA is currently at an all-time high

3-Year Low

-$19.02 M

Earnings dates

Last Annual Earnings Report Date

Dec 1, 2023
CYTO previous annual earnings announcement was published on Dec 1, 2023

Next Annual Earnings Report Date

N/A
CYTO next annual earnings announcement has not yet been scheduled

OtherCYTOprofitabilitymetrics:

Annual Revenue

$188.40 K
CYTO annual revenue is $188.40 thousand

Annual Net Income

-$2.12 M
CYTO annual net profit is -$2.12 million

Annual EBIT

-$1.87 M
CYTO annual earnings before interest & taxes is -$1.87 million

Annual EPS

-$1.43
CYTO annual earnings per share is -$1.43

Quarterly EBITDA

N/A

June 1, 2024

Summary

Performance

3-Month Change

-

1-Year Change

-

3-Year Change

-

5-Year Change

-

CYTO Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

-$1.45 M
CYTO quarterly EBITDA is currently at an all-time high

3-Year Low

-
CYTO quarterly EBITDA 3-year low is unknown

Earnings dates

Last Quarterly Earnings Report Date

Jun 1, 2024
CYTO previous earnings announcement was published on Jun 1, 2024

Next Quarterly Earnings Report Date

N/A
CYTO next earnings announcement has not yet been scheduled

OtherCYTOprofitabilitymetrics:

Quarterly Revenue

-
CYTO quarterly revenue value is unknown

Quarterly Net Income

-
CYTO quarterly net profit value is unknown

Quarterly EBIT

-
CYTO quarterly earnings before interest & taxes value is unknown

Quarterly EPS

-
CYTO quarterly earnings per share value is unknown

TTM EBITDA

N/A

June 1, 2024

Summary

Performance

3-Month Change

-

1-Year Change

-

3-Year Change

-

5-Year Change

-

CYTO TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

-$2.33 M
CYTO TTM EBITDA is currently at an all-time high

3-Year Low

-
CYTO TTM EBITDA 3-year low is unknown

Earnings dates

Last Quarterly Earnings Report Date

Jun 1, 2024
CYTO previous earnings announcement was published on Jun 1, 2024

Next Quarterly Earnings Report Date

N/A
CYTO next earnings announcement has not yet been scheduled

OtherCYTOprofitabilitymetrics:

TTM Revenue

-
CYTO TTM revenue value is unknown

TTM Net Income

-
CYTO TTM net profit value is unknown

TTM EBIT

-
CYTO TTM earnings before interest & taxes value is unknown

TTM EPS

-
CYTO TTM earnings per share value is unknown

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Annual EBITDA

-$1.87 M
CYTO annual EBITDA is -$1.87 million

Annual Net Income

-$2.12 M
CYTO annual net profit is -$2.12 million

Annual Interest Expense

$362.40 K
CYTO annual interest expense is $362.40 thousand

Annual Income Tax

-$117.70 K
CYTO annual income tax is -$117.70 thousand

Annual D&A

-
CYTO annual depreciation & amortization value is unknown

CYTO EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+90.2%--
3 y3 years+79.7%--
5 y5 years+81.7%--

CYTO EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+90.2%
5 y5-yearat high+90.2%
alltimeall timeat high+93.7%

Altamira Therapeutics EBITDA History

DateAnnualQuarterlyTTM
Dec 2023
-$1.87 M(-90.1%)
-
-
Dec 2022
-$19.02 M(+158.9%)
-
-
Dec 2021
-$7.35 M(-20.4%)
-
-
Dec 2020
-$9.23 M(+32.2%)
-
-
Dec 2019
-$6.98 M(-31.8%)
-
-
Dec 2018
-$10.24 M(-56.0%)
-$3.43 M(+18.2%)
-$10.35 M(-7.6%)
Sep 2018
-
-$2.90 M(+13.2%)
-$11.20 M(-20.1%)
Jun 2018
-
-$2.57 M(+77.0%)
-$14.01 M(-15.9%)
Mar 2018
-
-$1.45 M(-66.2%)
-$16.66 M(-28.1%)
Dec 2017
-$23.27 M(-20.6%)
-$4.28 M(-25.1%)
-$23.16 M(+2.5%)
Sep 2017
-
-$5.72 M(+9.8%)
-$22.59 M(-8.2%)
Jun 2017
-
-$5.21 M(-34.5%)
-$24.59 M(-12.1%)
Mar 2017
-
-$7.95 M(+114.2%)
-$27.96 M(-4.3%)
Dec 2016
-$29.32 M
-$3.71 M(-52.0%)
-$29.21 M(-4.5%)
Sep 2016
-
-$7.72 M(-10.0%)
-$30.59 M(+8.4%)
DateAnnualQuarterlyTTM
Jun 2016
-
-$8.58 M(-6.7%)
-$28.20 M(-10.3%)
Mar 2016
-
-$9.19 M(+80.6%)
-$31.43 M(+2.9%)
Dec 2015
-$29.95 M(+64.0%)
-$5.09 M(-4.7%)
-$30.53 M(+5.8%)
Sep 2015
-
-$5.34 M(-54.7%)
-$28.87 M(+6.8%)
Jun 2015
-
-$11.80 M(+42.2%)
-$27.04 M(+30.0%)
Mar 2015
-
-$8.30 M(+142.0%)
-$20.80 M(+9.0%)
Dec 2014
-$18.26 M(+10.9%)
-$3.43 M(-2.4%)
-$19.09 M(-2.7%)
Sep 2014
-
-$3.51 M(-36.8%)
-$19.63 M(-7.2%)
Jun 2014
-
-$5.56 M(-15.6%)
-$21.15 M(+2.1%)
Mar 2014
-
-$6.59 M(+66.1%)
-$20.72 M(+25.9%)
Dec 2013
-$16.46 M(+227.2%)
-$3.97 M(-21.2%)
-$16.46 M(+31.7%)
Sep 2013
-
-$5.03 M(-1.9%)
-$12.49 M(+67.5%)
Jun 2013
-
-$5.13 M(+120.4%)
-$7.46 M(+220.4%)
Mar 2013
-
-$2.33 M
-$2.33 M
Dec 2012
-$5.03 M
-
-

FAQ

  • What is Altamira Therapeutics annual EBITDA?
  • What is the all time high annual EBITDA for Altamira Therapeutics?
  • What is Altamira Therapeutics annual EBITDA year-on-year change?
  • What is the all time high quarterly EBITDA for Altamira Therapeutics?
  • What is the all time high TTM EBITDA for Altamira Therapeutics?

What is Altamira Therapeutics annual EBITDA?

The current annual EBITDA of CYTO is -$1.87 M

What is the all time high annual EBITDA for Altamira Therapeutics?

Altamira Therapeutics all-time high annual EBITDA is -$1.87 M

What is Altamira Therapeutics annual EBITDA year-on-year change?

Over the past year, CYTO annual EBITDA has changed by +$17.15 M (+90.15%)

What is the all time high quarterly EBITDA for Altamira Therapeutics?

Altamira Therapeutics all-time high quarterly EBITDA is -$1.45 M

What is the all time high TTM EBITDA for Altamira Therapeutics?

Altamira Therapeutics all-time high TTM EBITDA is -$2.33 M